Vantin: Advanced Cephalosporin Antibiotic for Effective Bacterial Infection Treatment
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.32 | $69.66 (0%) | 🛒 Add to cart |
| 60 | $1.92 | $139.32 $115.24 (17%) | 🛒 Add to cart |
| 90 | $1.79 | $208.98 $160.82 (23%) | 🛒 Add to cart |
| 120 | $1.73 | $278.64 $207.26 (26%) | 🛒 Add to cart |
| 180 | $1.66 | $417.96 $298.42 (29%) | 🛒 Add to cart |
| 270 | $1.61
Best per pill | $626.94 $436.02 (30%) | 🛒 Add to cart |
| Product dosage: 200mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $3.53 | $105.78 (0%) | 🛒 Add to cart |
| 60 | $2.92 | $211.56 $175.44 (17%) | 🛒 Add to cart |
| 90 | $2.72 | $317.34 $245.10 (23%) | 🛒 Add to cart |
| 120 | $2.62 | $423.12 $314.76 (26%) | 🛒 Add to cart |
| 180 | $2.53 | $634.68 $454.94 (28%) | 🛒 Add to cart |
| 270 | $2.46
Best per pill | $952.02 $663.06 (30%) | 🛒 Add to cart |
Synonyms
| |||
Vantin (cefpodoxime proxetil) is an advanced, third-generation oral cephalosporin antibiotic designed to combat a wide spectrum of bacterial pathogens. It is indicated for the treatment of various community-acquired infections, offering a reliable therapeutic option for both adult and pediatric populations. Its pharmacokinetic profile ensures effective tissue penetration and sustained antibacterial activity, making it a cornerstone in outpatient infection management. This product card provides a comprehensive, expert-level overview for healthcare professionals considering Vantin for their therapeutic arsenal.
Features
- Active ingredient: Cefpodoxime proxetil, a prodrug hydrolyzed to active cefpodoxime
- Available formulations: Oral tablets (100 mg, 200 mg) and granules for oral suspension (50 mg/5 mL, 100 mg/5 mL)
- Broad-spectrum activity against Gram-positive and Gram-negative bacteria, including Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Escherichia coli
- High oral bioavailability, with approximately 50% absorption unaffected by food
- Twice-daily dosing regimen for enhanced patient compliance
- FDA-approved for use in patients from 2 months of age and older
Benefits
- Provides potent bactericidal activity by inhibiting bacterial cell wall synthesis, leading to rapid pathogen eradication.
- Effective against common community-acquired pathogens, including β-lactamase-producing strains, reducing the need for broader-spectrum agents.
- Convenient oral administration facilitates outpatient treatment, potentially reducing hospitalization rates and healthcare costs.
- Demonstrated clinical efficacy in respiratory tract, skin, and urinary tract infections, supporting evidence-based prescribing.
- Favorable safety and tolerability profile, suitable for a wide demographic including pediatric patients.
- Minimizes risk of resistance development when used appropriately, supporting antimicrobial stewardship efforts.
Common use
Vantin is commonly prescribed for the treatment of mild to moderate infections caused by susceptible strains of designated microorganisms. Its primary indications include community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, acute otitis media, pharyngitis/tonsillitis, uncomplicated skin and skin structure infections, and acute uncomplicated urethral and cervical gonorrhea. It is also used for uncomplicated urinary tract infections caused by E. coli, Klebsiella pneumoniae, Proteus mirabilis, and Staphylococcus saprophyticus. The selection of Vantin should be based on local susceptibility patterns and individual patient factors.
Dosage and direction
Dosage varies based on infection type, severity, and patient factors. For adults and adolescents (age 12+): community-acquired pneumonia: 200 mg every 12 hours for 14 days; acute bacterial exacerbation of chronic bronchitis: 200 mg every 12 hours for 10 days; pharyngitis/tonsillitis: 100 mg every 12 hours for 5-10 days; uncomplicated skin infections: 400 mg every 12 hours for 7-14 days; uncomplicated UTI: 100 mg every 12 hours for 7 days; gonorrhea: single 200 mg dose. Pediatric dosing (5 months-12 years) is weight-based for otitis media (5 mg/kg every 12 hours for 5 days) and pharyngitis/tonsillitis (5 mg/kg every 12 hours for 5-10 days). Tablets should be administered with food to enhance absorption; suspension should be shaken well before use.
Precautions
Use with caution in patients with renal impairment (dose adjustment required for CrCl <30 mL/min). Monitor for superinfection or pseudomembranous colitis, which may occur during or after treatment. Use in pregnancy only if clearly needed (Category B). Exercise caution in breastfeeding women—cefpodoxime is excreted in human milk. May cause false-positive urinary glucose tests with Benedict’s or Fehling’s solution; use glucose oxidase methods. Prolonged use may result in fungal or bacterial overgrowth. Ensure adequate hydration to prevent crystalluria. Not recommended for treatment of meningitis due to inadequate cerebrospinal fluid penetration.
Contraindications
Vantin is contraindicated in patients with known hypersensitivity to cefpodoxime, other cephalosporins, or any component of the formulation. Cross-hypersensitivity may occur in patients allergic to penicillins; caution is advised in individuals with history of severe allergic reactions to β-lactam antibiotics. Should not be administered to patients who have experienced anaphylactic reactions to cephalosporins.
Possible side effect
Common adverse reactions (≥1%) include diarrhea (7%), nausea (4%), vaginal fungal infection (3%), abdominal pain (2%), and headache (2%). Less frequent side effects (<1%) include vomiting, rash, urticaria, pruritus, dizziness, and elevated liver enzymes. Serious but rare adverse events include Clostridium difficile-associated diarrhea, anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, and blood dyscrasias (neutropenia, thrombocytopenia). Discontinue therapy if severe hypersensitivity reactions or bloody diarrhea occurs.
Drug interaction
Probenecid may decrease renal tubular secretion of cefpodoxime, increasing serum concentrations. Antacids containing aluminum or magnesium may reduce absorption; administer Vantin at least 2 hours before or after antacids. H2-receptor antagonists may moderately decrease bioavailability. No significant interactions with warfarin have been observed, but monitor coagulation parameters when co-administering with anticoagulants. May reduce efficacy of oral typhoid vaccine; avoid concurrent use.
Missed dose
If a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Doubling doses to make up for a missed dose is not recommended. Maintain the regular dosing schedule to ensure consistent antibiotic levels. Inform patients about the importance of adherence to prescribed regimen for optimal therapeutic outcomes.
Overdose
Symptoms of overdose may include nausea, vomiting, epigastric distress, diarrhea, and convulsions. Cefpodoxime is not effectively removed by hemodialysis or peritoneal dialysis. Treatment should be symptomatic and supportive. Maintain adequate hydration and electrolyte balance. Monitor renal function closely. In cases of severe neurological symptoms, consider anticonvulsant therapy. There is no specific antidote for cefpodoxime overdose.
Storage
Store tablets at controlled room temperature (20-25°C/68-77°F) in original container. Keep tightly closed and protect from moisture. Reconstituted oral suspension should be stored in refrigerator (2-8°C/36-46°F) in original bottle; discard unused portion after 14 days. Do not freeze. Keep all medications out of reach of children and pets. Do not use beyond expiration date printed on packaging.
Disclaimer
This information is intended for healthcare professionals and should not replace clinical judgment. Prescribing decisions must be based on individual patient assessment, local susceptibility patterns, and official prescribing information. The prescribing physician should be familiar with complete product characteristics before administration. Dosage may require adjustment based on renal function, age, and infection severity. Not all possible interactions or side effects are listed here.
Reviews
Clinical studies demonstrate Vantin’s efficacy with cure rates of 85-95% across approved indications. In a multicenter trial of community-acquired pneumonia (n=315), clinical success was achieved in 92% of patients. For acute otitis media in pediatric patients, bacteriological eradication rates exceeded 88% against common pathogens. Dermatological studies showed 91% clinical cure rates in uncomplicated skin infections. Healthcare providers report good tolerability and convenience of twice-daily dosing. Some note the need for suspension refrigeration as a minor inconvenience. Overall, Vantin remains a valuable option for targeted antibiotic therapy in appropriate clinical scenarios.